- Home
- SKYE vs HQI Comparison
SKYE vs HQI Comparison
Compare SKYE & HQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- HQI
- Stock Information
- Founded
- SKYE 2012
- HQI 2002
- Country
- SKYE United States
- HQI United States
- Employees
- SKYE N/A
- HQI N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- HQI Professional Services
- Sector
- SKYE Health Care
- HQI Consumer Discretionary
- Exchange
- SKYE Nasdaq
- HQI Nasdaq
- Market Cap
- SKYE 172.9M
- HQI 172.8M
- IPO Year
- SKYE N/A
- HQI N/A
- Fundamental
- Price
- SKYE $5.36
- HQI $14.05
- Analyst Decision
- SKYE Strong Buy
- HQI Strong Buy
- Analyst Count
- SKYE 5
- HQI 2
- Target Price
- SKYE $18.40
- HQI $18.00
- AVG Volume (30 Days)
- SKYE 147.7K
- HQI 16.9K
- Earning Date
- SKYE 11-09-2024
- HQI 11-06-2024
- Dividend Yield
- SKYE N/A
- HQI 1.69%
- EPS Growth
- SKYE N/A
- HQI N/A
- EPS
- SKYE N/A
- HQI 0.37
- Revenue
- SKYE N/A
- HQI $36,133,000.00
- Revenue This Year
- SKYE N/A
- HQI N/A
- Revenue Next Year
- SKYE N/A
- HQI $7.62
- P/E Ratio
- SKYE N/A
- HQI $38.20
- Revenue Growth
- SKYE N/A
- HQI 3.96
- 52 Week Low
- SKYE $1.44
- HQI $11.39
- 52 Week High
- SKYE $19.41
- HQI $17.31
- Technical
- Relative Strength Index (RSI)
- SKYE 46.06
- HQI 54.35
- Support Level
- SKYE $5.71
- HQI $13.46
- Resistance Level
- SKYE $7.11
- HQI $14.79
- Average True Range (ATR)
- SKYE 0.56
- HQI 0.54
- MACD
- SKYE -0.02
- HQI 0.02
- Stochastic Oscillator
- SKYE 0.00
- HQI 65.34
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The primary source of revenue for the company is royalty fees based on the operation of its franchised offices.